AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38502074
Drug: Aspirin, 81
RxNorm normalized name: Aspirin, 81 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 81 mg once daily for 6 months
Trial: 38502074
Drug: Placebo, identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, identical pills once daily for 6 months
Trial: 38502193
Drug: Rapamycin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin dosing schedule
Trial: 38502195
Drug: FF-10101 (oral),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-10101 (oral), doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID)
Trial: 38502195
Drug: FF-10101 (oral),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-10101 (oral), recommended phase 2 dose was 75 mg BID
Trial: 38502425
Drug: Lacosamide 50
RxNorm normalized name: lacosamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 50 mg Bid for three months
Trial: 38502819
Drug: Combination Lavender/Peppermint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Lavender/Peppermint Aromatherapy Patch
Trial: 38503417
Drug: WT1/DC-vaccine immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WT1/DC-vaccine immunotherapy combined with conventional antiglioma treatment (chemoradiation with oral temozolomide 90 mg/m2)
Trial: 38503415
Drug: Weekly injections
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of semaglutide for 30 weeks
Trial: 38503755
Drug: Exemestane plus
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane plus everolimus and palbociclib (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane)
Trial: 38504173
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine (RZV), administered in two doses two months apart.
Trial: 38505928
Drug: FA-acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA-acetaminophen 1000 mg
Trial: 38505928
Drug: ES-acetaminophen 1000
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ES-acetaminophen 1000 mg
Trial: 38505928
Drug: LG-ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LG-ibuprofen 400 mg
Trial: 38506710
Drug: NOUS-PEV (vector-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOUS-PEV (vector-based personalized vaccine)
Trial: 38506889
Drug: MOABP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOABP with an oral regimen of neomycin and metronidazole (n=277)
Trial: 38506900
Drug: Cytotoxic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic treatments (chemo- and radiotherapy)
Trial: 38506900
Drug: Fertility preservation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fertility preservation treatments (freezing of gametes and gonadal tissue)
Trial: 38507476
Drug: CNS-active potentially
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS-active potentially inappropriate medication (PIM)
Trial: 38507476
Drug: Potential subadequate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential subadequate antidepressant dosing
Trial: 38507752
Drug: scAAV9/JeT-GAN (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy)
Trial: 38508135
Drug: KN046 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN046 plus chemotherapy (pemetrexed for non-sq-NSCLC and paclitaxel plus carboplatin for sq-NSCLC)
Trial: 38508835
Drug: Givinostat (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Givinostat (oral, flexible dose based on weight, twice a day for 72 weeks)
Trial: 38508835
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, twice a day for 72 weeks)
Trial: 38508844
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (Enalapril or Valsartan)
Trial: 38508877
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (other antihypertensive drugs)
Trial: 38508975
Drug: Topical diacerein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diacerein
Trial: 38509517
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of finerenone with an ACEi or ARB
Trial: 38509662
Drug: Smartphone-based speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based speech therapy app for 1 hour per day, 5 days per week, for 4 weeks, with guideline-based standard stroke care.
Trial: 38509699
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of RV5 and IPV
Trial: 38509699
Drug: Staggered administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staggered administration of RV5 and IPV
Trial: 38510299
Drug: End of
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End of anthracycline therapy
Trial: 38510299
Drug: CTRCD during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRCD during adjuvant therapy
Trial: 38510502
Drug: High HDL-C
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High HDL-C (>70 mg/dL)
Trial: 38510502
Drug: Low HDL-C
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low HDL-C (<50 mg/dL)
Trial: 38510502
Drug: Average HDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average HDL-C (50-70 mg/dL)
Trial: 38510979
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules containing polyunsaturated fatty acids (PUFAs) taken once daily for 12 months
Trial: 38510979
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsules containing olive oil (placebo)
Trial: 38510983
Drug: Vebicorvir (VBR)
RxNorm normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vebicorvir (VBR) + Nucleos(t)ide Reverse Transcriptase Inhibitors (NrtIs)
Trial: 38511087
Drug: Subcutaneous Ig20Gly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Ig20Gly (50-200 mg/kg) administered weekly for 24 weeks (Epoch 2)
Trial: 38511087
Drug: Subcutaneous Ig20Gly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Ig20Gly (100-400 mg/kg) administered every 2 weeks for 12 weeks (Epoch 3)
Trial: 38511087
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events during Epochs 2 and 3
Trial: 38511563
Drug: Mobocertinib at
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib at 160 mg once daily
Trial: 38512387
Drug: Basal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal Insulin Switch
Trial: 38512694
Drug: Vutrisiran (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vutrisiran (25 mg subcutaneous injection once every 3 months)
Trial: 38512694
Drug: Patisiran (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (0.3 mg/kg intravenous infusion once every 3 weeks)
Trial: 38512960
Drug: Delta variant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta variant infection (after 2 doses)
Trial: 38512960
Drug: Omicron BA.4/5
RxNorm normalized name: COVID-19 vacc, bv (Orig, Omicron BA.4/5) (Pfizer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omicron BA.4/5 infection (after 3 doses)
Trial: 38513060
Drug: Inorganic nitrate
RxNorm normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic nitrate (12 mmol potassium nitrate once daily for 5 days)
Trial: 38513170
Drug: PD-1/PD-L1 inhibitor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitor-based therapy
Trial: 38513368
Drug: mRNA-1273 (100-µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (100-µg doses)
Trial: 38513368
Drug: mRNA-1273 (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (after dose 2)
Trial: 38513368
Drug: mRNA-1273 (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (after dose 3)
Trial: 38513368
Drug: mRNA-1273 (post-additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (post-additional dose)
Trial: 38513436
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg biweekly)
Trial: 38513684
Drug: Co-administered Na-GST-1
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered Na-GST-1 on Alhydrogel plus Na-APR-1(M74) on Alhydrogel and glucopyranosyl lipid A in aqueous formulation (GLA-AF)
Trial: 38513684
Drug: Co-administered ENGERIX-B
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administered ENGERIX-B hepatitis B vaccine (HBV) and saline placebo
Trial: 38513689
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 µg) booster vaccination and QIV co-administered (Coad group)
Trial: 38513689
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 µg) booster vaccination and QIV sequentially administered (Seq group)
Trial: 38513746
Drug: Motion style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motion style acupuncture treatment (MSAT) combined with integrative Korean medicine (IKM)
Trial: 38513888
Drug: ω-3 FA
RxNorm normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily)
Trial: 38514081
Drug: Anti-PD-1 inhibitors
RxNorm normalized name: anti-inhibitor coagulant complex 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 inhibitors
Trial: 38515146
Drug: Enhanced cross-sectoral
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enhanced cross-sectoral collaboration and treatment during the first 3 months following diagnosis.
Trial: 38515149
Drug: Anlotinib-based therapy
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib-based therapy
Trial: 38515275
Drug: DISC-0974 (7-56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISC-0974 (7-56 mg, administered IV or SC)
Trial: 38515445
Drug: Cognito's Evoked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognito's Evoked Gamma Therapy System (CogTx-001), self-administered daily for one hour over 6 months.
Trial: 38515445
Drug: Sham treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment, self-administered daily for one hour over 6 months.
Trial: 38515445
Drug: Cognito's Evoked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognito's Evoked Gamma Therapy System (CogTx-001)
Trial: 38515570
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg administered by intravenous infusion on day 1 every 3 weeks (Q3W)
Trial: 38516099
Drug: Sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200 mg on day one and oral daily anlotinib 12 mg on days 1-14 once every three weeks per cycle
Trial: 38517235
Drug: Pralatrexate 25
RxNorm normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pralatrexate 25 mg/m²
Trial: 38517242
Drug: HBP levels
RxNorm normalized name: chlorpheniramine maleate Oral Tablet [Teldrin HBP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBP levels higher than 35 ng/mL
Trial: 38517907
Drug: albendazole-ivermectin treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: albendazole-ivermectin treatment
Trial: 38517907
Drug: albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: albendazole treatment
Trial: 38517907
Drug: hookworm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hookworm treatment (both arms)
Trial: 38518479
Drug: Online group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online group-based Acceptance and Commitment Therapy (ACT), 8 sessions as online group therapy.
Trial: 38518549
Drug: Domatinostat 200
RxNorm normalized name: Domatinostat
DrugBank: Domatinostat (DB17521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domatinostat 200 mg twice daily (BD) plus avelumab 10 mg/kg every 2 weeks (2qw)
Trial: 38518549
Drug: Domatinostat 200
RxNorm normalized name: Domatinostat
DrugBank: Domatinostat (DB17521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domatinostat 200 mg BD plus avelumab 10 mg/kg 2qw
Trial: 38518789
Drug: mRNA-1273.214 primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273.214 primary series (25 μg)
Trial: 38518789
Drug: mRNA-1273.214 booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273.214 booster dose (10 μg)
Trial: 38518789
Drug: mRNA-1273.214 primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273.214 primary series and booster dose
Trial: 38519053
Drug: GD2BATs (anti-CD3×anti-GD2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GD2BATs (anti-CD3×anti-GD2 bispecific antibody armed T cells)
Trial: 38519055
Drug: Odronextamab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab monotherapy
Trial: 38519416
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) 40,000 IU/mL weekly infusion
Trial: 38519581
Drug: MAG-EPA (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAG-EPA (3g daily for 7 weeks)
Trial: 38519581
Drug: Placebo (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3g daily for 7 weeks)
Trial: 38519913
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 3 weeks until progression or unmanageable toxicity, combined with SBRT (45 Gy in 3 fractions)
Trial: 38519988
Drug: Tocilizumab added
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab added to standard of care (SOC) maintenance treatment, n = 25
Trial: 38520501
Drug: Vortioxetine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5-20 mg)
Trial: 38520670
Drug: Pepinemab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pepinemab (20 mg/kg) administered intravenously on Days 1 and 15 of a 28-day cycle
Trial: 38521132
Drug: Once-daily radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily radiation therapy (66 Gy/33 fractions/6.5 weeks)
Trial: 38521132
Drug: Twice-daily radiation
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily radiation therapy (45 Gy/30 fractions/3 weeks)
Trial: 38521191
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (65.7 mg ferrous fumarate)
Trial: 38521524
Drug: Tailored anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks after 3 months of therapy.
Trial: 38521524
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of anticoagulant treatment for patients with high rVTE and low bleeding risk.
Trial: 38521524
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of anticoagulant treatment for patients with low rVTE risk after 3 months.
Trial: 38521533
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone antagonist given once daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Trial: 38521883
Drug: High-dose tafamidis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tafamidis (80/61 mg po qd)
Trial: 38521893
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg iberdomide
Trial: 38521931
Drug: Produce prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Produce prescription program (intervention)
Trial: 38522503
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum antimüllerian hormone (AMH) concentration
Trial: 38523000
Drug: PCSK9 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors (PCSK9i); 28% of patients
Trial: 38523332
Drug: Ad26.ZEBOV, MVA-BN-Filo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses from three consecutively manufactured lots)
Trial: 38523907
Drug: Multi-module music
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-module music therapy group (rhythm-guided walking and singing training)
Trial: 38523907
Drug: Multi-module music
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-module music therapy group
Trial: 38524266
Drug: Treatment-as-usual group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual group (TAU)
Trial: 38524688
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive sacroiliac posterior fusion LinQ allograft implant
Trial: 38524849
Drug: Immediate pressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate pressor response to oral salt (IPROS)
Trial: 38525605
Drug: Non-MRA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-MRA treatment
Trial: 38525699
Drug: Nurse-Implemented Music
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-Implemented Music Therapy intervention (structured over five weeks with ten 1-hour sessions, twice weekly)
Trial: 38525699
Drug: Nurse-Implemented Music
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-Implemented Music Therapy intervention
Trial: 38526047
Drug: AT-752 single
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-752 single dose up to 1,500 mg
Trial: 38526047
Drug: AT-752 multiple
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-752 multiple doses up to 750 mg three times daily (TID)
Trial: 38526047
Drug: AT-752 750
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-752 750 mg TID
Trial: 38526054
Drug: mRNA-1647 vaccine
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1647 vaccine (three-dose series)
Trial: 38526461
Drug: Nonspecific Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific Oral Migraine Preventives (OMPMs)
Trial: 38526612
Drug: Oxybutynin, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin, a muscarinic receptor antagonist, dosage and duration not specified
Trial: 38526764
Drug: NSE (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSE (same exercises performed twice a week at a physiotherapy clinic for 3 months)
Trial: 38526910
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control group C)
Trial: 38527605
Drug: Top 3
RxNorm normalized name: Nimotop 30mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Top 3 'more accurate' treatment success definitions (International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score ≤5, Urogenital Distress Inventory-6 score ≤33.3, no/mild stress urinary incontinence response on Urogenital Distress Inventory-6 question 3)
Trial: 38527849
Drug: Pascolizumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pascolizumab 2.5 mg/kg
Trial: 38527849
Drug: Pascolizumab 10
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pascolizumab 10 mg/kg
Trial: 38527849
Drug: Pascolizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pascolizumab (both doses)